Hepion Pharmaceuticals Inc 2026年季度报告

FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36856 (Exact name of registrant as specified in its charter) 46-2783806(I.R.S. EmployerIdentification Number) (State or other jurisdiction ofincorporation or organization) 34 Shrewsbury Ave., Suite 1DRed Bank, NJ 07701(Address of Principal Executive Offices) (732) 902-4000Registrant’s telephone number, including area code Securities registered pursuant to Section 12(b) of the Act: Name of each exchange on which registeredOTC QB HEPA Common Stock, par value $0.0001 per share Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that theRegistrant was required to submit such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smallerreporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerginggrowth company” in Rule 12b-2 of the Exchange Act.: Large accelerated filer☐Accelerated filer☐Non-accelerated filer☒Smaller reporting company☒Emerging growthcompany☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒The number of shares of the registrant’s Common Stock outstanding as of August 10, 2026 was 90,219,317. HEPION PHARMACEUTICALS, INC.FORM 10-QTABLE OF CONTENTS PagePART I—FINANCIAL INFORMATIONItem 1.Condensed Consolidated Financial Statements (unaudited):2Condensed Consolidated Balance Sheets2Condensed Consolidated Statements of Operations3Condensed Consolidated Statements of Comprehensive Loss4Condensed Consolidated Statements of Changes in Stockholders’ Equity5Condensed Consolidated Statements of Cash Flows6Notes to Condensed Consolidated Financial Statements7Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations16Item 3.Quantitative and Qualitative Disclosures About Market Risk22Item 4.Controls and Procedures22 Item 1A.Risk Factors23Item 6.Exhibits23SIGNATURES24 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q for Hepion Pharmaceuticals, Inc. may contain forward-looking statementswithin the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Suchforward-looking statements are characterized by future or conditional verbs such as “may,” “will,” “expect,” “intend,”“anticipate,” believe,” “estimate” and “continue” or similar words. You should read statements that contain these wordscarefully because they discuss future expectations and plans, which contain projections of future results of operations orfinancial condition or state other forward-looking information. Such statements are only predictions and our actual resultsmay differ materially from those anticipated in these forward-looking statements. We believe that it is important tocommunicate future expectations to investors. However, there may be events in the future that we are not able to accuratelypredict or control. Factors that may cause such differences include, but are not limited to, those discussed under Item 1A. RiskFactors and elsewhere in the audited consolidated financial statements as of and for the year ended December 31, 2025contained in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 12, 2026, as wellas under Item 1A . Risk Factors within this Form 10-Q. These factors include the uncertainties associated with: ●our ability to raise substantial additional capital to continue as a going concern and fund our planned operations in thenear term; ●estimates regarding our expenses, use of cash, timing of future cash needs and anticipated capital requirements;●success in retaining, or changes required in, our officers, key employees or directors;●our public securities’ potential liquidity and trading;●our ability to obtain and maintain regulatory approval of our product candidates, and any related restrictions, limitatio